肿瘤坏死因子α拮抗剂在强直性脊柱炎伴发葡萄膜炎的疗效研究OA
Efficacy study of tumor necrosis factor-α inhibitors in the treatment of uveitis associated with ankylosing spondylitis
目的 观察肿瘤坏死因子α(TNF-α)拮抗剂在强直性脊柱炎(AS)伴发葡萄膜炎的治疗效果.方法 多中心回顾性病例研究.收集2021年12月至2024年12月在宝鸡市人民医院和宝鸡市中心医院就诊并保存有完整电子病历资料的AS伴发葡萄膜炎患者87例(87只眼).其中男性75例,女性12例,年龄(30.7±13.2)岁(16~52岁).将入组患者按照是否联合使用TNF-α拮抗剂治疗分为两组,对照组43例常规激素点眼+非甾体抗炎药(NSAIDs)治疗,研究组44例在常规治疗基础上联合使用TNF-α拮抗剂.收集两组患者年龄、性别、病程,比较治疗前及治疗后1周、3周、2个月、3个月、6个月、12个月的房水细胞计数(AHCC)、最佳矫正视力(BCVA)、Bath强直性脊柱炎疾病活动指数(BASDAI)及随访12个月内葡萄膜炎复发情况.结果 两组患者治疗前一般资料比较,差异均无统计学意义(均P>0.05).治疗后1周及3周,两组AHCC、logMAR BCVA及BASDAI比较差异均无统计学意义(均P>0.05);治疗后2个月、3个月、6个月及12个月,研究组AHCC及BASDAI均低于对照组(均P<0.05);治疗后3个月、6个月及12个月,研究组logMAR BCVA低于对照组(均P<0.05).随访12个月内,对照组复发20例,复发率为46.51%;研究组复发11例,复发率为25.00%,两组比较差异有统计学意义(P=0.036).结论 TNF-α拮抗剂治疗AS伴发葡萄膜炎可降低房水细胞计数,改善logMAR BCVA,降低葡萄膜炎复发率,并减轻AS疾病活动度,是AS伴发葡萄膜炎患者的一种有效治疗策略.
Objective To evaluate the therapeutic efficacy of tumor necrosis factor-α(TNF-α)antagonists in patients with ankylosing spondylitis(AS)-associated uveitis.Methods This was a multicenter retrospective case series study.A total of 87 patients with AS-associated uveitis who were treated in Baoji People's Hospital and Baoji Central Hospi-tal between December 2021 and December 2024 and had complete electronic medical records were included.Among them,75 were male and 12 were female,with a mean age of(30.7±13.2)years(range,16~52 years).Patients were divided into two groups according to whether they received TNF-α antagonist therapy.The control group included 43 patients who re-ceived conventional topical corticosteroid eye drops combined with nonsteroidal anti-inflammatory drugs(NSAIDs),while the study group included 44 patients who received TNF-α antagonists in addition to conventional treatment.Age,sex,and disease duration were collected.Aqueous humor cell count(AHCC),the best-corrected visual acuity(BCVA),Bath Ankylos-ing Spondylitis Disease Activity Index(BASDAI),and uveitis recurrence during the 12-month follow-up were compared be-tween the two groups before the treatment and at 1 week,3 weeks,2 months,3 months,6 months and 12 months after the treatment.Results There were no statistically significant differences in baseline characteristics between the two groups be-fore the treatment(all P>0.05).At 1 and 3 weeks after the treatment,there were no statistically significant differences in AHCC,logMAR BCVA,or BASDAI between the two groups(all P>0.05).At 2,3,6 and 12 months after the treatment,AHCC and BASDAI were lower in the study group than in the control group(all P<0.05).At 3,6 and 12 months after the treatment,logMAR BCVA was lower in the study group than in the control group(all P<0.05).During the 12-month follow-up,recurrence occurred in 20 patients in the control group,with a recurrence rate of 46.51%,and in 11 patients in the study group,with a recurrence rate of 25.00%.The difference between the two groups was statistically significant(P=0.036).Conclusions TNF-α antagonist therapy for AS-associated uveitis can reduce aqueous humor cell count,improve logMAR BCVA,lower the recurrence rate of uveitis,and reduce AS disease activity.It may represent an effective therapeu-tic strategy for patients with AS-associated uveitis.
丁国鹏;谢桂军;张淼;刘涛;丁国龙;雷姝
721000 陕西宝鸡,宝鸡市人民医院721000 陕西宝鸡,宝鸡市人民医院721000 陕西宝鸡,宝鸡市人民医院721000 陕西宝鸡,宝鸡市中心医院710002 陕西西安,西安市第一医院721000 陕西宝鸡,宝鸡市妇幼保健院
强直性脊柱炎葡萄膜炎非甾体抗炎药肿瘤坏死因子拮抗剂
Ankylosing spondylitisUveitisNonsteroidal anti-inflammatory drugsTumor necrosis factor-α an-tagonist
《临床眼科杂志》 2026 (4)
322-326,5
评论